Media headlines about Coherus Biosciences (NASDAQ:CHRS) have trended positive on Sunday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Coherus Biosciences earned a media sentiment score of 0.32 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.2606643025526 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several equities research analysts recently issued reports on CHRS shares. BidaskClub downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. ValuEngine downgraded shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, Citigroup reissued a “buy” rating and issued a $23.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Coherus Biosciences has an average rating of “Buy” and a consensus target price of $29.67.

Shares of Coherus Biosciences (NASDAQ:CHRS) traded up $0.05 during trading hours on Friday, reaching $9.45. 753,647 shares of the company were exchanged, compared to its average volume of 739,674. Coherus Biosciences has a fifty-two week low of $8.05 and a fifty-two week high of $26.55. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46. The company has a market capitalization of $547.58, a PE ratio of -1.74 and a beta of 3.81.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/11/positive-press-coverage-somewhat-unlikely-to-impact-coherus-biosciences-chrs-share-price.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.